# Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML

> **NCT05264883** · PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 170 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax-Decitabine/Azacitidine-Aclarubicin Association
- **DRUG:** Venetoclax-Decitabine/Azacitidine Association

## Key facts

- **NCT ID:** NCT05264883
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-01
- **Primary completion:** 2023-06-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 170 (ESTIMATED)
- **Last updated:** 2023-05-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05264883

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05264883, "Venetoclax+HMA+Aclarubicin Versus Venetoclax+HMA in Treatment-Naive Elderly Patients With AML". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05264883. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*